reports
Gritstone bio Reports First Quarter 2024 Financial Results and Provide...
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates -- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024 -- -- Nature Medicine publication of Phase 1 study of SLATE (off-the-shelf neoantigen vaccine) and AACR-presented improvements to EDGE™ (tumor antigen identification platform that was recently enhanced using ...
Gritstone bio to Report First Quarter 2024 Financial Results and Provi...
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024 -- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm...
Gritstone bio Highlights the Durability and Potential Broad Utility of...
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024 -- IgG levels and neutralizing antibodies against variants of concern persisted for at least 12 months, consistent with previous findings -- -- Antigen-specific T cell responses increased in the majority of participants studied, including those living with HIV, after administration of any of the samRNA constructs -- -- Comprehensive data set demonstrates a consistent and strong immunogenicity profile across multiple patient populations in South Af...
Gritstone bio Announces Appointment of Stephen Webster to its Board of...
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the appointment of Stephen Webster to its Board of Directors. A veteran finance executive in the biotechnology industry, Mr. Webster has served as an executive for several renowned companies and held key roles in raising capital, business development transactions and operations for over 30 years. The company also ...
Live Oak Bancshares, Inc. Reports First Quarter 2024 Results
Live Oak Bancshares, Inc. Reports First Quarter 2024 Results WILMINGTON, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Live Oak Bancshares, Inc. (NYSE: LOB) (“Live Oak” or “the Company”) today reported first quarter of 2024 net income of $16.5 million, or $0.36 per diluted share. “The Live Oak model continued to prove its fortitude in the first quarter as our teams marched ahead to steadily grow both sides of the balance sheet and delivered exceptional service to our customers,” said Live Oak Chairman and CEO James S. (Chip) Mahan III. “In a challenging environment for our industry, I remain ...
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1...
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE) -- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. Rosenberg of the National Cancer Institute (NCI) -- -- Publication underscores the important role of antigen selection and ...
Live Oak Bancshares, Inc. Announces Date of First Quarter 2024 Financi...
Live Oak Bancshares, Inc. Announces Date of First Quarter 2024 Financial Results WILMINGTON, N.C., April 10, 2024 (GLOBE NEWSWIRE) -- Live Oak Bancshares, Inc. (“Live Oak”) (NYSE: LOB) today announced that it will report its first quarter 2024 financial results after U.S. financial markets close on Wednesday, April 24, 2024. In conjunction with this announcement, Live Oak will host a conference call to discuss the company's financial results and business outlook on Thursday, April 25, 2024, at 9:00 a.m. ET. The call will be accessible by telephone and webcast using Conference ID: 501852...
Gritstone bio to Participate in Upcoming Investor and Scientific Confe...
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences. Select events (marked by *) will be webcasted live and webcast details will be available on the ‘Events’ page of Gritstone bio’s website: . Archived replays will be accessible for 30 days following each event. 23rd Annual Need...
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024 -- State-of-the-art neoantigen prediction platform (EDGE™) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly available models -- -- Combined with Gritstone's vaccine vectors, EDGE has demonstrated best-in-class potential in identifying neoantigens capable of eliciting T cell immune responses for robust and durable immunity -- EMERYVILLE, Calif., April 08, 2024 ...
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public O...
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwriting di...
Gritstone bio Announces Proposed Public Offering
Gritstone bio Announces Proposed Public Offering EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof). All of the shares of common stock, pre-funded warrants and accompanying ...
Gritstone bio Announces Positive Preliminary Progression-free Survival...
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) -- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction of progression or death with GRANITE vs. control) in a high-risk group, where clinical data are more mature (...
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Resu...
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates -- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone’s personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC) remain expected in 1Q 2024 -- -- National Cancer Institute-led Phase 1 study evaluating Gritstone's "off-the-shelf" cancer vaccine, SLATE, combined with neoantigen cell therapy expected to begin in the coming months -- -- Gritstone incorporating GMP-grade raw materials in the manufacture of i...
- Jonathan Moreland
TRS TRIMAS CORPORATION
TLYS TILLYS
SEDG SOLAREDGE TECHNOLOGIES INC.
LOB LIVE OAK BANCSHARES
GOGO GOGO INC.
D DOMINION ENERGY INC
CTRN CITI TRENDS INC.
AFT APOLLO SENIOR FLOATING RATE FUND INC.
PLBC PLUMAS BANCORP
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
FMN FEDERATED PREMIER MUNICIPAL INCOME FUND
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
FPF FIRST TRUST INTERMEDIATE DURATION PREFERRED AND INCOME FUND
KSM DWS STRATEGIC MUNICIPAL INCOME TRUST
PCB PACIFIC CITY FINANCIAL CORP
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
VPV INVESCO PA VALUE MUNI INC TST
BHRB BURKE HERBERT FINANCIAL SERVICES CORP
MDRX ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS
INC.
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
SHBI SHORE BANCSHARES INC.
PNNT PENNANTPARK INVESTMENT
NGL NGL ENERGY PARTNERS LP
LOB LIVE OAK BANCSHARES
HOO HERBALIFE NUTRITION LTD.
FFIN FIRST FINANCIAL BANKSHARES INC
EMKR EMCORE CORP.
CTBI COMMUNITY TRUST BANCORP INC.
CRMT AMERICA'S CAR-MART INC.
CFFN CAPITOL FEDERAL FINANCIAL INC.
ATRC ATRICURE INC.
ASYS AMTECH SYSTEMS INC.
HWBK HAWTHORN BANCSHARES
RIGN TRANSOCEAN LTD.
PLBC PLUMAS BANCORP
HCC WARRIOR MET COAL INC.
IOVA IOVANCE BIOTHERAPEUTICS INC
NANX NANOPHASE TECHNOLOGIES CORP.
CSPI CSP INC.
FSK FS KKR CAPITAL CORP
NOVA SUNNOVA ENERGY INTERNATIONAL
MRBK MERIDIAN
PLCE THE CHILDREN'S PLACE RETAIL STORES
LRMR INC.
THRY LARIMAR THERAPEUTICS INC
ABCL THRYV HOLDINGS
LUMN ABCELLERA BIOLOGICS
SANA LUMEN TECHNOLOGIES INC.
ONDS SANA BIOTECHNOLOGY
WES ONDAS HOLDINGS
TRST WESTERN MIDSTREAM PARTNERS LP
STGW TRUSTCO BANK CORP NY
MODD STAGWELL INC
VFC MODULAR MEDICAL INC
GATO VF CORPORATION
CYT SUNSHINE SILVER MINING AND REFINING CORP
ADXS CYTEIR THERAPEUTICS INC
BNL AYALA PHARMACEUTICALS INC
BROADSTONE NET LEASE INC
Gritstone bio Announces Workforce Reduction
Gritstone bio Announces Workforce Reduction EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced an approximately 40% reduction of its workforce. The move comes following the recently announced delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving external funding it previously anticipated beginning in 1Q 2024, associated with the initiation of the study. “The lack of near-term funding necessitated this difficul...
- Jonathan Moreland
PNNT PENNANTPARK INVESTMENT
NYCB NEW YORK COMMUNITY BANCORP INC.
NGL NGL ENERGY PARTNERS LP
NBTB NBT BANCORP INC.
MKL MARKEL CORPORATION
LOB LIVE OAK BANCSHARES
HOO HERBALIFE NUTRITION LTD.
FFIN FIRST FINANCIAL BANKSHARES INC
EMKR EMCORE CORP.
CVBF CVB FINANCIAL CORP.
CTBI COMMUNITY TRUST BANCORP INC.
CRMT AMERICA'S CAR-MART INC.
CPRX CATALYST PHARMACEUTICALS
ASYS AMTECH SYSTEMS INC.
ADVM ADVERUM BIOTECHNOLOGIES
VIRT VIRTU FINANCIAL INC. CLASS A
HWBK HAWTHORN BANCSHARES
THR THERMON GROUP HOLDINGS
HI HILLENBRAND INC.
PLBC PLUMAS BANCORP
CIZN CITIZENS HOLDING CO.
CLSD CLEARSIDE BIOMEDICAL INC
KREF KKR REAL ESTATE FINANCE TRUST
NEE NEXTERA ENERGY
IOVA INC.
NANX IOVANCE BIOTHERAPEUTICS INC
CSPI NANOPHASE TECHNOLOGIES CORP.
PLCE CSP INC.
LRMR THE CHILDREN'S PLACE RETAIL STORES
LUMN INC.
SANA LARIMAR THERAPEUTICS INC
TRST LUMEN TECHNOLOGIES INC.
MODD SANA BIOTECHNOLOGY
BPRN TRUSTCO BANK CORP NY
VFC MODULAR MEDICAL INC
CYT BANK OF PRINCETON
PCSA VF CORPORATION
ADXS CYTEIR THERAPEUTICS INC
PROCESSA PHARMACEUTICALS INC
AYALA PHARMACEUTICALS INC
- Jonathan Moreland
Gritstone bio to Participate in Upcoming Investor and Scientific Confe...
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences EMERYVILLE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences: 2024 BIO CEO & Investor Conference (Panel)Panel Title: Reviewing Vaccine Pipeline Breakthroughs and BarriersDate and Time: Monday, February 26, 2024 at 2:00pm ETLocation: New York, NY IO360 Summit (Panel)Panel Title: How to us...
Live Oak Ventures Participates in Financing of Anatomy Financial
Live Oak Ventures Participates in Financing of Anatomy Financial WILMINGTON, N.C., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Live Oak Ventures, the investment arm of Live Oak Bancshares, Inc., has announced an investment in Anatomy Financial, an AI-powered financial automation solution for medical, dental, digital health, and healthcare billing companies. “Live Oak is excited to invest in companies such as Anatomy Financial that solve hard problems for small business owners,” said Stephanie Mann, Live Oak Bank Chief Strategy Officer. “As a bank that understands the difficulty and importance of...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.